Please assess the completion status of the following clinical trial:

Trial Title: Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study related procedures.~* postmenopausal or ovariectomised female patient over 18 years of age.~* histologically confirmed diagnosis of ER positive endometrial carcinoma in the primary tumour or metastatic disease~* patient has received one line of chemotherapy prior to enrolment in the adjuvant or in the metastatic setting (including chemoradiotherapy) and progressed after this line of chemotherapy~* patient has at least one measurable disease site (RECIST criteria version 1.1)~Exclusion Criteria:~* patient has received hormone therapy for endometrial cancer in the adjuvant or metastatic setting~* patient has received more than one line of chemotherapy in the adjuvant or metastatic setting~* patient was treated with any other investigational agent within the 3 weeks before study entry.~* patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade (NCI CTCAE) or QTcF interval \>460 msec.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BN83495 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).